Content Type: Article

  • 2022 FDA Year in Review

    2022 FDA Year in Review

    ARTICLE / REPORT

    2022 FDA Year in Review

    February 2023

    Read time: 4 min

    Overview

    As the United States’ primary public health and consumer protection agency, the US Food and Drug Administration (FDA) regulates at least one quarter of the nation’s economy and exerts significant influence over global economies. The agency’s reach continues to expand with the proliferation of outsourced and offshore manufacturing, clinical trials and global supply chains. The past year was notable for FDA’s continued efforts to align and scale its regulatory processes to keep pace with growing innovation in drug and device development and food production, and the rise and market dominance of in vitro diagnostics (IVDs), including laboratory-developed tests (LDTs), in the wake of the COVID-19 pandemic. Congress’s failure to enact the long-awaited and hotly contested Verifying Accurate Leading-edge IVCT Development (VALID) Act, which would have expanded FDA’s authority over LDTs, increases the likelihood that VALID will be on the legislative agenda in 2023. The drive toward modernization has also prompted a reexamination of established regulatory programs such as expedited review pathways for drugs and devices. As the number and corresponding financial import of breakthrough designations increase, the agency is under greater pressure to assess whether these programs have fulfilled their original goals of improving patient outcomes in areas of unmet need and clearing the path for innovative products.

    FDA continues to tussle with industry and courts regarding the scope of its discretion to interpret decades-old statutory provisions. As it has in the past, the agency seeks to expand the bounds of its interpretative authority, and courts continue to chip away at the degree of deference afforded to the agency. In the areas of drug and device regulation and digital health (i.e., the Software Pre-Certification Pilot Program), FDA has conceded the need for affirmative legislative authority and congressional intervention to respond to judicial pushback and regulatory complexities inherent in its responses to innovation. While FDA’s various user-fee-related bills were for the most part passed without any revisions to the Federal Food, Drug, and Cosmetic Act (FDCA), legislative intervention came in the form of the Consolidated Appropriations Act, 2023 (2023 Omnibus), which contained the Food and Drug Omnibus Reform Act (FDORA), signed by President Biden on December 29, 2022. The 2023 Omnibus enacted a subset of the provisions contemplated in various user fee acts that enhance FDA’s authority to address public health emergencies (PHEs), protect the drug supply chain, impose stricter cybersecurity requirements on medical devices and support greater access to generic drugs.

    While enforcement declined in 2022, the steady march toward normalization of factory inspections and post-market surveillance activities may signal an increase in enforcement as FDA and the world emerges from the global pandemic. The finalization of key guidance documents for clinical decision support (CDS) and food labeling may also signal increased scrutiny in those sectors in 2023.

    The FDA regulatory environment will be as complex and dynamic as ever in 2023. FDA will continue to implement new policies, reexamine old programs and normalize processes to encourage greater engagement with industry-significant policy issues. It remains to be seen how much the agency will accomplish and what it will prioritize before the start of the 2024 presidential election cycle, where healthcare will undoubtedly drive the agenda in a post-pandemic environment.

     

    McDermott Will & Emery staff attorney, Christine Dower, also contributed to this report.

    In depth
    Tabs

    Michael W. Ryan

    Partner

    Washington, DC

    Alva C. Mather

    Partner

    Washington, DC

    More insights
    Endnotes

  • Practical Derivatives: A Transactional Approach, Fourth Edition

    Practical Derivatives: A Transactional Approach, Fourth Edition

    ARTICLE

    Practical Derivatives: A Transactional Approach, Fourth Edition

    February 2023

    Read time: 2 min

    Key takeaways
    Overview

    Fausto Giacomet co-authored the chapter “ESG Derivatives” (pages 631 to 666) featured in Practical Derivatives: A Transactional Approach, Fourth Edition. 

    In depth
    Authors
    More insights

  • Revision of the AIFM and UCITS Directive – Current Status and Outlook

    Revision of the AIFM and UCITS Directive – Current Status and Outlook

    ARTICLE / CLIENT ALERT

    Revision of the AIFM and UCITS Directive – Current Status and Outlook

    February 6, 2023

    Read time: 2 min

    Key takeaways
    Overview

    EU Commission, Parliament and Council are entering the critical stage of negotiations on reviewed versions of the AIFM and the UCITS Directive. Amendments have been drafted especially with regard to delegation, loan originating funds and liquidity management tools. This article summarizes the main topics under discussion and gives an overview on the further legislative procedure.

    In depth
    Authors
    More insights

  • Third Circuit Dismisses J&J Bankruptcy Case for Lack of Good Faith

    Third Circuit Dismisses J&J Bankruptcy Case for Lack of Good Faith

    ARTICLE / CLIENT ALERT

    Third Circuit Dismisses J&J Bankruptcy Case for Lack of Good Faith

    February 6, 2023

    Read time: 8 min

    Key takeaways
    Overview

    “The theme is clear: absent financial distress, there is no reason for Chapter 11 and no valid bankruptcy purpose.”

    On Jan. 30, 2023, the U.S. Court of Appeals for the Third Circuit dismissed the Chapter 11 bankruptcy case of LTL Management LLC, a Johnson & Johnson entity created to hold billions in liabilities stemming from J&J’s talc products, after finding that the case was not filed in good faith. See In re LTL Management, LLC, No. 22-2003, 2023 BL 28442 (3d. Cir. Jan. 30, 2023). The decision reversed rulings of the Bankruptcy Court for the District of New Jersey noting that the bankruptcy court erred by focusing its analysis on the financial wellbeing of LTL’s predecessor instead of LTL itself.

    As the Court explained, “[w]e start, and stay, with good faith . . . What counts to access the Bankruptcy Code’s safe harbor is to meet its intended purpose. Only a putative debtor in financial distress can do so. LTL was not.” This case could potentially impact certain companies’ ability to file for bankruptcy in the Third Circuit (which includes the Delaware Bankruptcy Court) – and certainly creates uncertainty around eligibility. It also strikes a blow against large companies using strategies like the so-called “Texas two-step” merger to cabin off liabilities – exposing the larger corporate entities to those broader liabilities.

    The Good Faith Requirement

    Section 1112(b) of the Bankruptcy Code requires a bankruptcy court to dismiss a Chapter 11 case for “cause,” which can include a finding that the case was not filed in good faith. Courts consider the totality of the circumstances, but one particularly important inquiry is whether the petition serves a valid bankruptcy purpose. “[A] debtor who does not suffer from financial distress cannot demonstrate its Chapter 11 petition serves a valid bankruptcy purpose supporting good faith.”

    The “Texas Two-Step” & LTL’s Funding Agreement

    J&J formed LTL two days prior to LTL’s Chapter 11 filing through a form of divisional merger allowed under Texas law. Under the transaction, an existing subsidiary of J&J named Johnson and Johnson Consumer Inc. (“Old Consumer”) allocated essentially all of its talc-related tort liabilities to a new entity named LTL Management LLC. Concurrently, Old Consumer assigned its operating assets to a different new entity also named Johnson & Johnson Consumer Inc. (“New Consumer”) – effectively severing the assets from the liabilities. LTL’s assumption of Old Consumer’s liabilities meant that LTL “would take the place of Old Consumer in current and future talc lawsuits and be responsible for their defense.” At the same time the actual assets from which those liabilities derived had been moved to New Consumer which would continue operating. To effectuate this strategy for ring-fencing liabilities, J&J relied on provisions of Texas state law that “splits a legal entity in two, divides its assets and liabilities between two new entities, and terminates the original entity.” People have commonly called this transaction, a “Texas two-step” divisional merger.

    As part of the transaction, LTL also entered into a multi-billion-dollar funding agreement with J&J and New Consumer. Under the funding agreement, J&J and New Consumer agreed, jointly and severally, to pay LTL cash up to the value of New Consumer ($61.5 billion at the time of the merger) for purposes of satisfying talc-related costs and LTL’s normal course expenses.

    The Bankruptcy Court Finds a Good Faith Bankruptcy Filing

    Shortly after LTL filed its Chapter 11 petition in New Jersey, certain talc claimants moved to dismiss the case under § 1112(b) by arguing that it was not filed in good faith. Judge Kaplan, the Chief Judge of the Bankruptcy Court for the District of New Jersey, found that LTL’s case was filed in good faith and denied the motions to dismiss. Judge Kaplan based his opinion, in part, on a finding that LTL was in financial distress due to the scope of litigation against Old Consumer, the costs Old Consumer incurred in defending such litigation and the effect of those lawsuits on Old Consumer’s business. The talc claimants appealed the ruling directly to the Third Circuit.

    The Third Circuit Reverses the Bankruptcy Court

    The Third Circuit disagreed with Judge Kaplan’s approach, finding that LTL was not in financial distress at the time of filing and that its Chapter 11 case was therefore not filed in good faith. The Court wrote that Judge Kaplan erred by focusing on Old Consumer’s liabilities and litigation costs instead of testing the financial wellbeing of the debtor LTL, “independent of any other entity.” The Court explained that the correct analysis should have focused “on [LTL’s] assets, liabilities, and, critically, the funding backstop it has in place to pay those liabilities.” Old Consumer should be considered only to the extent it “informs [the court’s] view of the financial condition of LTL itself.”

    LTL’s multi-billion-dollar funding agreement with New Consumer and J&J was particularly significant. The Court wrote that the “[a]greement provided LTL a right to cash that was very valuable, likely to grow, and minimally conditional. And this right was reliable, as J&J and New Consumer were highly creditworthy counterparties (an understatement) with the capacity to satisfy it.” Given LTL’s “$61.5 billion payment right against J&J and New Consumer,” the Court “[could not] agree LTL was in financial distress when it filed its Chapter 11 petition.”

    The Court stopped short of laying out a specific test for evaluating financial distress, writing instead that “[t]hough insolvency is not strictly required…we cannot ignore that a debtor’s balance-sheet insolvency or insufficient cash flows to pay liabilities (or the future likelihood of these issues occurring) are likely always relevant.”

    The Court’s opinion instructs Judge Kaplan to dismiss the case.

    Takeaways

    This ruling could impact bankruptcies in the Third Circuit (and beyond) significantly.

    • While the Bankruptcy Code has never required a showing of insolvency to file for bankruptcy, the Third Circuit has now added a requirement that a debtor be in “financial distress.” Congress does not require such distress – though Court rulings on “good faith” have often considered the Debtor’s financial state.
    • The Court noted that consideration of “financial distress” and good faith should focus on the Debtor’s financial well-being – not the well-being of other non-filing entities.
    • While the Third Circuit does not rule as to the propriety of the “Texas two-step” divisional merger per se, surely Debtors will need to think carefully before utilizing such strategies prior to filing for bankruptcy in the Third Circuit. Companies looking to isolate mass tort claims via a separate entity in bankruptcy must carefully structure the bifurcation of assets and liabilities between the parent and bankruptcy-bound subsidiaries. As the Court put it, “the bigger a backstop a parent company provides a subsidiary, the less fit that subsidiary is to file.”
    • This is part of a recent series of cases in which creditors have questioned the fairness of bankruptcies designed to limit parental liabilities for potential tort or other mass liabilities. The victim claimants in the Purdue Pharma L.P. bankruptcy challenged potential non-debtor releases for the owners of officers of the debtors – before settling on appeal. And tort claimants in the Aearo Technologies LLC bankruptcy are seeking dismissal of the case as also filed in bad faith. In Aearo the victims recently argued that the Bankruptcy Court for the Southern District of Indiana should consider the Third Circuit’s ruling in LTL and dismiss the case. However the debtors in Aearo will assert the facts there vary from the facts here – Aearo was a long-existing subsidiary of 3M that recently filed for bankruptcy.

    Authored by Douglas S. Mintz, Robert D. Brown and Kelly (Bucky) Knight.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2023 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • Preparing for New Consumer Privacy Laws in Colorado, Connecticut and Utah

    Preparing for New Consumer Privacy Laws in Colorado, Connecticut and Utah

    ARTICLE / CLIENT ALERT

    Preparing for New Consumer Privacy Laws in Colorado, Connecticut and Utah

    February 3, 2023

    Read time: 7 min

    Key takeaways
    Overview

    We would not blame companies for feeling fatigued after the race to comply with the amended California Consumer Privacy Act (CCPA), the soon-to-be finalized CCPA regulations and the new Virginia Consumer Data Protection Act (CDPA) requirements. For some companies, however, these events were simply mile markers in the race to comply with Connecticut and Colorado’s new laws coming into effect on July 1, 2023, and Utah’s new law on December 31, 2023. For others, one of these upcoming state laws will be the first time that your company will need to build a US consumer privacy program. Either way, the Global Privacy and Cybersecurity team at McDermott Will & Emery is here to assist.

    In depth

    WHO IS COVERED?

    Closely resembling Virginia’s CDPA, the application of the Colorado Privacy Act (CPA), Connecticut’s Personal Data Privacy Act (PDPA) and Utah’s Consumer Privacy Act (UCPA) depends in large part on the number of residents of each respective state whose information is processed by a company. In Colorado and Connecticut, companies that do business or offer good or services in Colorado or Connecticut and control the processing of 100,000 or more residents in each state are subject to the new laws. In Utah, a company is subject to the UCPA if the company does business or offers good or services in Utah and has annual global revenue of at least $25 million and controls the processing of at least 100,000 Utah residents. The other way that these new laws could be triggered is if a receives revenue (25% or more of its annual revenue in Connecticut) from the sale of (or receipt of discounts for in Colorado) personal information, including through the sale of the data for at least 25,000 residents in each state. Of course, each state law also contains a variety of exemptions for companies subject to federal laws, such as the Gramm–Leach–Bliley Act (GLBA), the Health Insurance Portability and Accountability Act (HIPAA) and the Family Educational Rights and Privacy Act (FERPA).

    Critically, however, the CPA applies to nonprofit organizations, that produce or deliver commercial goods or services in Colorado, which makes it an outlier among the laws coming into effect in 2023. If you are a nonprofit organization (for example, a hospital), Colorado will likely be the first time that you must contend with these new consumer privacy laws.

    WHAT  IS REQUIRED?

    Targeted Advertising

    Connecticut, Colorado and Utah will give consumers the right to opt out of targeted advertising, which is generally defined as displaying a digital advertisement that is based on personal information obtained or inferred over time across nonaffiliated websites or applications. Both Connecticut and Colorado require that companies provide methods outside of a company’s privacy policy for consumers to opt out of targeted advertising. In Connecticut, that means providing a static link on a home page. In Colorado, the opt-out must be “clear and conspicuous, and readily accessible.” These requirements are likely to require even businesses that already have an opt-out link on their website to comply with the CCPA.

    While many businesses engaging in targeted advertising already have an opt-out link on their home page to comply with the CCPA, the Colorado and Connecticut laws will likely require updates to these links given the proscriptive nature of the CCPA’s “Do Not Sell or Share” language, which may not “conspicuously” communicate the opt-out of targeted advertising required by Connecticut and Colorado.

    Action item: If engaging in targeted advertising for consumers in Colorado and Connecticut, place an opt-out link on your website or update your existing opt-out link.

    Sensitive Personal Information

    Each of the new state laws that take effect in 2023 have rules regarding “sensitive” data. Most of the new state laws treat ethnicity, religious beliefs, mental and physical health diagnoses, sexual orientation, citizenship, specific geolocation, biometric and genetic information, and the information of a known child as sensitive. Like Virginia, Colorado and Connecticut require consumer consent before a business can collect this type of information. In contrast, Utah requires that companies offer consumers the opportunity to opt out of a company collecting this type of information.

    Notably, the draft Colorado regulations (which are not yet finalized) also require businesses to add disclosures in their privacy policies related to sensitive data inferences (e.g., inferring religious beliefs or medical conditions from a dietary preference).

    Action item: Ensure that you have a consent or opt-out mechanism in place if you are collecting sensitive personal information and sensitive personal information inferences.

    Data Protection Assessments

    Colorado and Connecticut’s new laws require companies to prepare data protection assessments in the event that they are (1) engaged in targeted advertising; (2) selling personal data; (3) profiling where the profiling could have a legally significant impact on the consumer (e.g., credit decisions); or (4) processing sensitive data. These assessments are critical compliance pieces that companies may need to provide to regulators upon request. Companies that have already performed these assessments to comply with other laws will still need to refresh them to account for data processing activities related to Colorado and Connecticut residents. Companies will also need to keep an eye out for California’s next wave of CCPA rulemaking which will make effective the CCPA’s requirements to conduct data protection assessments.

    Action item: Update or prepare data protection assessments for regulated data processes.

    Consumer Appeal Rights

    Companies that have implemented compliance programs for the Virginia law may already have a system in place for addressing consumer appeal rights, but if not, the new laws in Colorado and Connecticut will require them. Colorado and Connecticut require a company to implement an internal appeal process by which a consumer can challenge a company’s prior decision not to honor a consumer rights request. In addition to designing this internal process, companies must inform consumers in privacy policies and responses to rights requests about their right to appeal and the process for doing so.

    Action item: Implement or expand the scope of your internal data subject request appeal process and update privacy policies and template rights request response materials to include information about the right.

    No Employee or B2B Data

    The good news for many companies is that each of the Colorado, Connecticut and Utah laws expressly exempt from coverage employee data and business contact information. California remains the only state where that information is in scope.

    Action item: Nothing!

    WHAT’S NEXT?

    We have highlighted some of the key obligations that companies will face to prepare for the effective dates of the new laws in Colorado, Connecticut and Utah. However, what each company must do to comply with the new laws likely will vary based on each company’s current compliance posture. And, of course, the work starts with a thorough examination of whether a company is subject to these new consumer privacy laws in the first instance.

    If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to Elliot Golding, Kathryn Linsky, Amy Pimentel or David Saunders.

    Authors

    Elliot R. Golding

    Partner

    Washington, DC

    Kathryn Linsky

    Partner

    New York – One Vanderbilt Avenue

    Amy C. Pimentel

    Partner

    Boston

    David P. Saunders

    Partner

    Chicago

    More insights

  • Court of Chancery Holds That Corporate Officers Owe Duty of Oversight in Sexual Harassment and Misconduct Case

    Court of Chancery Holds That Corporate Officers Owe Duty of Oversight in Sexual Harassment and Misconduct Case

    ARTICLE / CLIENT ALERT

    Court of Chancery Holds That Corporate Officers Owe Duty of Oversight in Sexual Harassment and Misconduct Case

    February 3, 2023

    Read time: 8 min

    Key takeaways
    Overview

    On January 25, 2023, the Delaware Court of Chancery held, for the first time, that the rationale for a duty of oversight (Caremark duty) owed by directors of Delaware corporations applies equally, if not to a greater degree, to officers. In re McDonald’s Corp. Stockholder Derivative Litigation, C.A. No. 2021-0324-JTL (Del. Ch. Jan. 25, 2023).

    However, this officer duty of oversight will be more context-driven than the duty owed by directors. Some officers, like a chief executive officer or a chief compliance officer, will have company-wide oversight duties while other officers with more constrained areas of responsibility will have a more constrained duty of oversight (i.e., establishing information reporting systems and upward reporting of red flags will be based on the particular officer’s responsibilities and authority). Additionally, as with a director’s duty of oversight, oversight liability for officers will require a showing of bad faith, meaning a plaintiff will need to establish that the officer consciously failed to make a good faith effort to establish information reporting systems or consciously ignored red flags.

    In depth

    FACTS AND HOLDING

    McDonald’s Corporation stockholders asserted derivative claims against the board of directors and certain officers of McDonald’s, including David Fairhurst, who served as Executive Vice President and Global Chief People Officer from 2015 until his termination with cause in 2019. Fairhurst was the head of human resources and was the executive officer with day-to-day responsibility of ensuring that McDonald’s provided its employees with a safe and respectful workplace. During his tenure at McDonald’s, the stockholders alleged that Fairhurst breached his fiduciary duties by allowing a corporate culture to develop that condoned sexual harassment and misconduct. Specifically, the stockholders asserted that Fairhurst breached his duty of oversight by failing to exercise adequate oversight in response to risks of sexual harassment and misconduct at McDonald’s. The stockholders also alleged that Fairhurst himself committed acts of sexual harassment while employed at McDonald’s.

    Fairhurst moved to dismiss the stockholders’ claim that he breached his duty of oversight and asserted that Delaware law does not recognize a duty of oversight for officers. In denying the motion, the Court held that officers have the same fiduciary duties as directors, including the duty of oversight. In Caremark (In re Caremark International Inc. Derivative Litigation, 698 A.2d 959 (Del. Ch. 1996)) and its progeny (including Stone v. Ritter, 911 A.2d 362, 370 (Del. 2006), wherein the Delaware Supreme Court adopted the reasoning in Caremark), Delaware courts have held that directors have a duty of oversight, which encompasses two obligations: (1) to ensure that information and reporting systems exist in the organization and (2) to properly address red flags indicative of wrongdoing within those information and reporting systems that come to the attention of the board. These same two obligations are required of officers. However, an officer’s duty of oversight is limited to the area of the corporation to which he or she is responsible, provided that a particularly egregious red flag may require an officer to act even if such red flag falls outside of an officer’s area of responsibility. The Court further stated that duty of oversight liability for an officer requires actions that constitute bad faith (i.e., the officer must consciously fail to make a good faith effort to establish information systems, or the officer must consciously ignore red flags), which would be a breach of the duty of loyalty, and not just actions that constitute gross negligence, which would only be a breach of the duty of care. The Court, in a scholarly discussion, clarified that while the duty of oversight can encompass both the duty of care and the duty of loyalty, liability against an officer for breach of the duty of oversight will only apply to claims of a breach of the duty of loyalty (a Caremark claim, which requires a showing of bad faith), meaning plaintiffs will not be able to survive a motion to dismiss on a duty of oversight claim by pleading mere gross negligence (i.e., duty of care violation).

    The Court further concluded that the stockholders adequately pled that Fairhurst breached his duty of oversight by consciously ignoring red flags and permitted McDonald’s to develop a toxic culture that turned a blind eye to sexual harassment and misconduct. The Court pointed to multiple allegations that Fairhurst failed to adequately address employee complaints of discrimination during his tenure at McDonald’s.

    CASE TAKEAWAYS

    • This case is the first instance of a Delaware court holding that officers owe the same duty of oversight as directors, but it also limits liability for the duty of oversight to claims that sound in bad faith (Caremark claims) and not claims that sound in gross negligence. This decision expands the path for stockholders (and plaintiffs’ lawyers) to pursue duty of oversight claims against officers and not just directors, however, any such claims must be brought derivatively on behalf of the corporation, meaning a plaintiff must make a demand on the board of directors to bring such a claim (and the board will have the discretion whether to bring or not bring the claim) or such demand must be excused due to the board suffering from a disabling conflict of interest.
    • As of August 1, 2022, a corporation can provide in its certificate of incorporation (either in its initial certificate of incorporation or by amendment with approval by the board of directors and the stockholders) that officers cannot be subject to monetary liability for claims that an officer acted with gross negligence (a duty of care breach), unless such claim is brought by or in the right of the corporation. While such an exculpatory provision in a certificate of information will not protect officers from duty of oversight (Caremark) claims (since such claims are derivative in nature (brought in the right of the corporation) and are based on allegations of bad faith as opposed to mere gross negligence), we recommend that corporations (particularly publicly-traded corporations) still seriously consider adopting such officer exculpation provisions in order to protect officers from direct stockholder claims of alleged breach of the duty of care (g., disclosure claims).
    • An officer will have a constrained duty of oversight limited to the area of responsibility he or she has been delegated (g., an officer responsible for human resources will only have a duty of oversight as to human resources but not as to other areas of the company). However, an officer with a broader scope of responsibility will have a broader duty of oversight (e.g., a chief executive officer will have a company-wide duty of oversight).
    • To state a viable Caremark claim against an officer, a complaint will need to articulate facts that demonstrate a sustained or systematic failure of an officer to exercise oversight over his or her area of responsibility. This means facts must be alleged showing that the officer consciously failed to make a good faith effort to establish information systems, or the officer consciously ignored red flags:
      • Information-Systems: In order for a “information-systems” duty of oversight claim to survive a motion to dismiss for failure to state a claim, a plaintiff must plead facts supporting an inference that an officer completely failed to implement any reporting or information system, or controls and such failure was a sustained or systematic failure done in bad faith.
      • Red Flags: In order for a “red flags” duty of oversight claim to survive a motion to dismiss for failure to state a claim, a plaintiff must plead facts supporting an inference that the officer knew of evidence of corporate misconduct and an inference that the officer consciously failed to take action in response. Furthermore, such pled facts must support an inference that the failure to act was sufficiently sustained, systematic or striking to constitute action in bad faith. The mere existence of red flags is not enough to support a duty of oversight claim under the “red flags” theory.

    Should you have any questions regarding the impact of this holding, please contact one of the authors of this article or your regular McDermott lawyer.

    Authors

    Nathan E. Barnett

    Partner

    Wilmington

    Ethan H. Townsend

    Partner

    Wilmington

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Benjamin Strauss

    Partner

    Wilmington

    Marina C. Leary

    Associate

    Washington, DC, Wilmington

    More insights

  • CMS Finalizes Long-Awaited Rule on Medicare Advantage RADV Audits

    CMS Finalizes Long-Awaited Rule on Medicare Advantage RADV Audits

    ARTICLE / CLIENT ALERT

    CMS Finalizes Long-Awaited Rule on Medicare Advantage RADV Audits

    February 3, 2023

    Read time: 6 min

    Key takeaways
    Overview

    On January 30, 2023, the Centers for Medicare & Medicaid Services (CMS) finalized a rule related to Medicare Advantage (MA) Risk Adjustment Data Validation (RADV) audits that eliminates the so-called fee-for-service (FFS) adjuster from CMS’s methodology for extrapolating audit findings but limits extrapolation to plan years 2018 and beyond. For audits conducted between 2011 and 2017, CMS will only collect non-extrapolated overpayments identified. CMS has not yet conducted audits for 2018 or later. The final rule directly affects MA organizations (MAOs) and is also of interest to providers (particularly risk-bearing providers) and risk adjustment vendors.

    In depth

    BACKGROUND

    CMS is required to risk-adjust the monthly capitation payments it makes to MAOs, based on the health status of an MAO’s enrollees, in order to eliminate any disincentives for plans to enroll individuals with greater healthcare needs and higher expected costs. CMS does so based on diagnosis codes that MAOs submit for each enrollee based on the enrollee’s encounters with healthcare providers.

    CMS has conducted annual RADV audits of a limited number of MA plans. In RADV audits, CMS confirms that the risk adjustment conditions for a sample of the MAO’s enrollees are supported in medical records from the providers who treated the member. If they are not, CMS recalculates the payment to the MAO and recovers any differential.

    The final rule addresses CMS’s ability and methodology for extrapolating the results of these RADV audits. In the final rule, CMS reversed an extrapolation methodology it had previously adopted in 2012.

    FFS ADJUSTER

    CMS reversed the 2012 methodology’s inclusion of a so-called FFS adjuster. The statutory requirement for “actuarial equivalence” between MA and traditional FFS Medicare has been the subject of substantial policy action and litigation for more than a decade. The final rule did not rely on an analysis that CMS had initially published with the proposed rule. Rather, CMS cited two key legal bases for its decision not to include an FFS adjuster:

    • Actuarial Equivalence. The final rule asserts that the statutory requirement of “actuarial equivalence” applies to how rates are set but does not apply to collections of improper payments, relying on a 2021 decision by the US Court of Appeals for the District of Columbia Circuit. In that case, the Court distinguished between plan-identified overpayments from RADV audits and expressed no opinion on whether the actuarial-equivalence requirement requires an FFS adjuster in RADV audits.
    • Minimum Coding Pattern Adjustment. The Social Security Act requires the implementation of a minimum coding pattern adjustment to reduce risk scores of MA beneficiaries to account for differences in the coding patterns between MA and Medicare FFS. CMS asserts that the existence of the statutory coding intensity adjustment supports its conclusion that no FFS adjuster is required: “the only reasonable interpretation of the [Social Security] Act is that CMS would pay MAOs at those reduced rates . . . and enforce the longstanding documentation requirements through CMS’ audits.”

    APPLICATION TO PENDING AND PAST PLAN YEAR AUDITS

    The final rule provides that CMS may collect extrapolated overpayments identified in either CMS RADV or US Department of Health and Human Services Office of Inspector General (OIG) audits for the 2018 plan year and later. CMS cites practical reasons for its decision not to extrapolate for years 2011through 2017, including that this approach will allow CMS to focus on conducting future RADV audits as soon as practicable after an MAO payment year concludes and will reduce a possible backlog of RADV audit appeals. CMS expects that this decision will better control the total number of active appeals that are submitted in the first few years following finalization of the rule.

    Still, the rule will apply to four already-completed payment years (2018 to 2022). CMS asserts that the rule is not “retroactive” because the medical record documentation requirement remains unchanged: proper medical documentation is required for diagnosis codes to be deemed valid. CMS also explains that the documentation requirement applies equally whether CMS calculates audit recoveries on an enrollee-by-enrollee basis or uses a statistically valid sample of enrollees to extrapolate results. CMS states that even if the methodology were determined to be a retroactive application of policy, retroactive application is appropriate and permissible under the statute because it is necessary to comply with statutory requirements and doing so is in the public interest.

    The final rule estimates that applying extrapolation to audit findings beginning with the 2018 payment year audits will produce more than $428 million in net recovery. The total estimated recovery amount between 2023 and 2032 is $4.7 billion.

    OTHER NOTABLE PROVISIONS

    • Contract-Wide Versus Sub-Cohort. The final rule gives CMS authority to use any statistically significant sampling and extrapolation methodology. This could include contract-wide samples or “sub-cohort” samples (e.g., beneficiaries with an assigned diabetes hierarchical condition code, with extrapolation to the population from which the sample was drawn, such as all enrollees in the sub-cohort in that payment year. The specific methodology will be announced via sub-regulatory guidance and may change from audit to audit. CMS asserts that this approach will allow it to spread its audit resources across a wider range of contracts while focusing its audit efforts where there is greatest risk of overpayments.
    • Selection of MA Plans to Audit. CMS does not specify how many MA plans will be selected for each year’s RADV audit. The rule’s preamble states that CMS will select MA plans that “through statistical modeling and/or data analytics, are identified as being at highest risk for improper payments.” CMS noted that this approach was previously recommended by the US Government Accountability Office.
    • OIG Audits. When OIG performs audits, it refers its results to CMS for collection and appropriate action, rather than collecting directly. According to the preamble, the rule also applies to audits conducted by OIG. Thus, CMS will not extrapolate audits performed by OIG for plan years prior to 2018, but the rule states that CMS may extrapolate and recover amounts based on OIG audit results for 2018 and later. CMS will collect enrollee-level overpayments identified in OIG audits.
    • Process for Pending Audits. CMS intends to finalize and make recoveries for the currently pending RADV audits on a rolling basis beginning April 1, 2023. These audits will not be extrapolated, as all pending RADV audits are for years prior to 2018.
    Authors

    Jeremy Earl

    Partner

    Washington, DC

    Emily R. Curran

    Associate

    Washington, DC

    More insights

  • FinCEN Identifies Bitzlato as a “Primary Money Laundering Concern” in First-Time Use of Section 9714(a) and DOJ Charges Its Founder with Owning an Unlicensed Money Transmitting Business

    FinCEN Identifies Bitzlato as a “Primary Money Laundering Concern” in First-Time Use of Section 9714(a) and DOJ Charges Its Founder with Owning an Unlicensed Money Transmitting Business

    ARTICLE / CLIENT ALERT

    FinCEN Identifies Bitzlato as a “Primary Money Laundering Concern” in First-Time Use of Section 9714(a) and DOJ Charges Its Founder with Owning an Unlicensed Money Transmitting Business

    February 3, 2023

    Read time: 8 min

    Key takeaways
    Overview

    On Jan. 18, 2023, the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) issued an order[1] (“Order”) identifying Bitzlato Limited (“Bitzlato”), a Hong Kong-based virtual currency exchange with global operations, as a financial institution of “primary money laundering concern” in connection with illicit Russian finance. FinCEN’s Order bars any covered financial institution from engaging in certain transmittals of funds involving Bitzlato. FinCEN’s Order marks the first order issued under Section 9714(a) of the Combating Russian Money Laundering Act.

    In a coordinated action, the Department of Justice (“DOJ”) arrested Bitzlato’s founder and majority-owner, Anatoly Legkodymov, for conducting an unlicensed money transmitting business under 18 U.S.C. § 1960.[2] Both the Order and the DOJ’s complaint and arrest warrant highlight that Bitzlato had severe and pervasive anti-money laundering (“AML”) deficiencies and significant connections to Russia and Russian illicit finance.

    Section 9714(a)

    The Combating Russian Money Laundering Act (“Act”) was enacted in 2021 as part of the 2021 National Defense Authorization Act, which included other notable anti-money laundering-related legislation (such as the Anti-Money Laundering Act of 2020 and the Corporate Transparency Act). Section 9714(a) of the Act allows FinCEN to, upon determining “reasonable grounds for concluding” that one or more covered financial institutions operating outside of the U.S. is of “primary money laundering concern in connection with Russian illicit finance,” prohibit or impose conditions upon certain transmittals of funds by any domestic financial institution . . . ”[3]

    Noting that FinCEN has long interpreted the term “financial institutions” to cover “money transmitters,” including entities that accept and transmit value that substitutes for currency (like convertible virtual currencies (“CVCs”)),[4] FinCEN highlights Bitzlato’s exchange and peer-to-peer (“P2P”) services as reason for Bitzlato to constitute a “financial institution” for the purposes of Section 9714(a) of the Act.

    FinCEN’s Findings

    To support its conclusion that Bitzlato is a “financial institution operating outside of the United States of primary money laundering concern in connection with Russian illicit finance,” FinCEN alleges four separate patterns of behavior underlying its assessment.

    • Facilitating Processing and Laundering of Funds Used to Finance Ransomware Attacks. The Order asserts that Bitzlato plays a significant role in facilitating transactions for various ransomware groups that have connections to illicit Russian finance, including Conti. Specifically, FinCEN notes that it has documented transactions between Conti-associated CVC addresses and Bitzlato. In addition, the Order indicates that, based on blockchain analysis, other ransomware groups and OFAC-designated virtual asset service providers (“VASPs”) have used Bitzlato to facilitate transactions. FinCEN notes that Bitzlato “provides an enabling environment for such ransomware criminals to utilize its services to cash out ransomware proceeds due to its minimal Anti-Money Laundering/Countering the Financing of Terrorism (AML/CFT) protocols, solidifying its reputation as a go-to CVC exchanger for such groups.”[5]
    • Facilitating Darknet Markets and Scams. The Order also finds that Bitzlato’s incoming and outgoing transactional activity reflect connections to counterparties that are associated with darknet markets and scams with connections to and operations in Russia. In particular, the Order states that certain of Bitzlato’s top incoming and outgoing counterparties (such as Hydra, a Russia-connected darknet market, and the alleged Russia-based Ponzi scheme “TheFiniko”) are associated with such illicit activities.
    • Engaging in Illicit Russian Finance Transactions. FinCEN alleges that, based on analysis conducted by a blockchain analytics company, the value of transactions that involve illicit Russian finance or “otherwise risky sources” made up 48 percent of all Bitzlato transactions between 2019 and 2021.[6]
    • Failing to Combat Anti-Money Laundering and Illicit Finance. According to the Order, publicly-available information indicates that, despite featuring a “Know Your Client [(KYC)] policy” on its website, Bitzlato does not implement effective policies and procedures to combat AML and illicit finance.[7] Specifically, the Order highlights language on Bitzlato’s website that suggests “simple registration” that only requires an email address to create an account on the platform.[8] Such a procedure runs counter to common, effective AML controls, such as collecting more thorough identifying information about the customer.

      In addition, the Order describes Bitzlato’s policy of user privacy and anonymity, allowing users to exchange fiat currency and cryptocurrency directly with another person, as well as transfers to and from financial institutions and other methods. Bitzlato advertises that its users do not need to go through the same KYC procedures that are typically required on other exchanges. FinCEN notes that this anonymous exchange policy, along with the advertised “simple registration” process, is indicative of ineffective AML/CFT controls.

    Order Requirements and Penalties

    The Order prohibits “covered financial institutions,” which are defined to include, among other entities, banks, broker-dealers, money services businesses, mutual funds, futures commission merchants and introducing brokers in commodities,[9] from engaging in transmittals of funds to or from Bitzlato, as well as to or from “any account or CVC address administered by or on behalf of Bitzlato.”[10] Should a covered financial institution receive CVC from Bitzlato or from an account administered by or on behalf of Bitzlato, FinCEN notes that it would not be a violation of the Order for the covered financial institution to “reject” the transaction by: “(1) preventing the intended recipient from accessing such CVC; and (2) returning the CVC to Bitzlato, or to the account or CVC address from which the CVC originated.”[11] FinCEN also notes that covered financial institutions are not required to reject such CVC transfers where doing so would violate sanctions laws.[12]

    FinCEN notes that previous transactions involving Bitzlato do not violate the Order, but expects covered financial institutions to “take such steps that a reasonable and prudent financial institution would take to identify any transactions that are prohibited by the Order, including determining risk exposure with any person associated with Russian illicit finance or violations of applicable law.”[13] In addition, FinCEN underscores that the Order does not impose any additional Suspicious Activity Reporting (“SAR”) requirements on covered financial institutions but encourages covered financial institutions to “consider, as warranted and appropriate, Bitzlato’s identification as a primary money laundering concern related to Russian illicit finance” in connection with existing SAR obligations.[14]

    The terms of the Order became effective Feb. 1, 2023, with no cessation date. Penalties for noncompliance with the Order, which applies to officers, directors, employees and agents of covered financial institutions, could include civil or criminal penalties under 31 U.S.C. §§ 5321 and 5322.

    Conclusion

    The Order, as well as the fact that it marks FinCEN’s first action under Section 9714(a) of the Act, reflect an aggressive stance by FinCEN to take action against entities engaging in Russian illicit finance as its jurisdiction permits. In light of the deficiencies identified by FinCEN — primarily as it relates to AML/KYC policies and procedures — non-U.S. VASPs and covered financial institutions should take care to ensure their AML/KYC controls are up-to-date, efficient and effective. In addition, covered domestic financial institutions should ensure that, beginning on February 1, they are not engaging in covered transactions with Bitzlato.

    Schulte Roth & Zabel’s lawyers are available to assist you in addressing any questions you may have regarding these developments. Please contact the Schulte Roth & Zabel lawyer with whom you usually work, or any of the following attorneys:

    Donald J. Mosher – New York (+1 212.756.2187, donald.mosher@srz.com)

    Betty Santangelo – New York (+1 212.756.2587, betty.santangelo@srz.com)

    Melissa G.R. Goldstein – Washington, DC (+1 202.729.7471, melissa.goldstein@srz.com)

    Kara A. Kuchar – New York (+1 212.756.2734, kara.kuchar@srz.com)

    Adam J. Barazani – New York (+1 212.756.2519, adam.barazani@srz.com)

    Jessica Romano – New York (+1 212.756.2205, jessica.romano@srz.com)

    Jessica Sklute – New York (+1 212.756.2180, jessica.sklute@srz.com)

    Hadas A. Jacobi – New York (+1 212.756.2055, hadas.jacobi@srz.com)

    Rebecca A. Raskind – New York (+1 212.756.2396, rebecca.raskind@srz.com)

    Jesse Weissman – New York (+1 212.756.2460, jesse.weissman@srz.com)


    [1] U.S. Department of the Treasury, Financial Crimes Enforcement Network, Imposition of Special Measure Prohibiting the Transmittal of Funds Involving Bitzlato, 88 Fed. Reg. 3919 (Jan. 23, 2023), available here [hereinafter “Order”]; Press Release, Financial Crimes Enforcement Network, FinCEN Identifies Virtual Currency Exchange Bitzlato as a “Primary Money Laundering Concern” in Connection with Russian Illicit Finance (Jan. 18, 2023), available here.

    [2] Press Release, U.S. Department of Justice, Founder and Majority Owner of Bitzlato, a Cryptocurrency Exchange, Charged with Unlicensed Money Transmitting (Jan. 18, 2023), available here.

    [3] Section 9714 (as amended) can be found in a note to 31 U.S.C. § 5318A.

    [4] Order, 88 Fed. Reg. at 3920.

    [5] Id. at 3922.

    [6] Id.

    [7] Id. at 3923.

    [8] Id.

    [9] 31 C.F.R. § 1010.100(t).

    [10] Order, 88 Fed. Reg. at 3926.

    [11] U.S. Department of the Treasury, Financial Crimes Enforcement Network, Frequently Asked Questions: Section 9714 Order Prohibits Certain Transmittals of Funds Involving Bitzlato (Jan. 18, 2023) [hereinafter FAQs], available here, at 4.

    [12] Id.

    [13] Id. at 5.

    [14] Id. at 5.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2023 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    More insights

  • Biden Administration Takes Steps to Reinforce Nursing Home Safeguards

    Biden Administration Takes Steps to Reinforce Nursing Home Safeguards

    ARTICLE / CLIENT ALERT / US POLICY

    Biden Administration Takes Steps to Reinforce Nursing Home Safeguards

    February 2, 2023

    Read time: 7 min

    Key takeaways
    Overview

    In connection with the Biden-Harris administration’s stated goals of improving safety, transparency, accountability and quality in nursing homes, the US Centers for Medicare & Medicaid Services (CMS) have announced new actions to further nursing home safeguards. These actions include targeting the inappropriate use of antipsychotic medications and revamping their Special Focus Facility (SFF) Program to improve overall nursing home quality.

    In depth

    In the last quarter of 2022 and the first quarter of 2023, CMS has taken material steps to advance the Biden-Harris administration’s intentions of promoting nursing home safety, transparency, accountability and quality. Specifically, on October 21, 2022, CMS announced revisions to its Special Focus Facility (SFF) Program, which focuses on the country’s poorest-performing nursing facilities. And on January 18, 2023, CMS announced new actions to help reduce inappropriate use of antipsychotic medications in the senior services industry. We review these developments in this alert.

    I. Strengthening Nursing Home Safety and Transparency

    To strength nursing home safety and transparency, CMS is adjusting their quality measure ratings of facilities that are inappropriately coding residents as having schizophrenia. CMS is also posting citations under dispute on the “Nursing Home Care Compare” website to allow individuals and families more access to information.

    1. CMS to Reinforce Safeguards against Unnecessary Medications and Treatments

    To continue progress toward decreasing inappropriate use of antipsychotic medications in nursing homes, CMS announced that, beginning in January 2023, they will be conducting targeted and off-site audits to better understand how and if nursing homes are utilizing codes for patients with a schizophrenia diagnosis. Historically, nursing home residents that have been misdiagnosed with schizophrenia are at risk of overuse and misuse of antipsychotic drugs and overall poor quality of care.

    CMS uses the Five-Star Quality Rating System to rate nursing homes, using three categories: health inspections, staffing and quality measures. The use of antipsychotic medication is one indicator, among others, used to assess the quality of care that nursing homes provide residents. However, CMS identified a gap in this indicator, as it excluded residents that have been diagnosed with certain psychiatric illnesses such as schizophrenia, Huntington’s disease or Tourette syndrome. CMS is addressing this gap by flagging facilities that display a pattern of inaccurately coding a resident as having schizophrenia. CMS will then downgrade the quality measure rating for any audits that reveal inaccurate coding practices, a step that will negatively impact such facilities’ overall ratings. After monitoring the flagged facilities and determining whether any quality of care issues occurred, CMS will have the option to reverse downgrades.

    CMS also plans to make public the results of its schizophrenia diagnosis code audits, thereby advancing the administration’s objective of increasing transparency and quality of nursing home care.

    2. CMS to Post Citations under Dispute on Care Compare

    CMS also plans to increase transparency by disclosing citations that facilities are actively disputing. Nursing homes can dispute citations through the Informal Dispute Resolution (IDR) process. When CMS imposes a civil monetary penalty, nursing homes can request an Independent IDR (IIDR). Currently, when a facility is involved with IDR or IIDR and disputing a survey deficiency, the deficiency is not made publicly available. The deficiency is only posted after the investigation is complete, which typically averages around 60 days but can last up to six months. CMS acknowledges that deficiencies range in severity and may be determined to be a non-issue after investigation; however, circumstances may also include severe instances of non-compliance, such as when residents of a facility could be at risk for serious injury, harm, impairment or even death.

    Rather than waiting for an investigation’s completion, CMS will instead post citations to Nursing Home Care Compare immediately upon issuance, adding a flag if the deficiency is disputed. By displaying deficiencies before the dispute process is complete, CMS is furthering its efforts to provide timely and relevant information to patients and families so that they can make more informed choices while evaluating a facility.

    The up-to-date information under this initiative began appearing on Nursing Home Care Compare on January 25, 2023.

    II. Strengthening Oversight of Poorest-Performing Nursing Homes

    In addition to the most recent actions described above, CMS also has implemented changes to its Special Focus Facility (SFF) Program to increase scrutiny and hold facilities accountable for substandard safety, quality and care for residents.

    1. Making Requirements Tougher

    When CMS and state regulatory agencies survey nursing homes and identify deficiencies, the facility is required to correct cited issues or risk disqualification from Medicare and Medicaid. Deficiencies are not rare, with most nursing homes needing to fix six to seven issues within a timely basis. Some nursing homes have more difficulties than others in maintaining consistent compliance practices and routinely demonstrate repeated cycles of serious deficiencies. To assist these facilities, CMS implemented the SFF Program for those with the highest number of deficiencies —particularly, those scoring high in scope and severity. Each state identifies between five and 30 such facilities to participate in the SFF program, during which the facilities are inspected twice annually and provided with recommendations for improvement. When appropriate, CMS will impose progressive enforcement sanctions, including civil monetary penalties and denied claims, until the facility graduates from the SFF Program or is excluded from further participation.

    Effective October 21, 2022, CMS began efforts to strengthen the criteria for graduation from the SFF Program. To that end, CMS has decided that facilities cannot leave the SFF Program without demonstrating systemic improvements in quality. This includes achieving two consecutive health surveys with 12 or fewer deficiencies scored at a scope and severity of “E” or lower. A facility will not graduate if there are more than 13 deficiencies at any level or if any of the deficiencies are classified as “F” level or higher, as those deficiencies put a resident at risk for serious harm, injury or death.

    2. Enforcement Actions for Facilities That Do Not Improve

    To avoid a facility remaining in the SFF Program for a prolonged period, CMS is considering discretionary termination from Medicare and/or Medicaid programs for all facilities cited with a severe or immediate jeopardy deficiency on any two surveys while the facility is in the SFF Program.

    CMS is also planning to impose harsher enforcement remedies for SFF Program participating facilities that have continued noncompliance and little to no improvement. CMS has historically retained discretion on decisions regarding graduation and termination based on individualized factors from each facility, and it will explore its options while weighing a facility’s good-faith effort to improve.

    3. Incentivizing Sustainable Improvements

    CMS will be closely monitoring graduates from the SFF Program for up to three years to ensure any improvements that were targeted during the program are sustained. For nursing home facilities that graduate and proceed to demonstrate noncompliance, such as poor quality of care, actual harm or severe deficiencies, CMS may use increased enforcement action to terminate the facility from the Medicare and/or Medicaid programs. Relatedly, nursing homes that participate in the SFF Program for three surveys without graduating will be required to discuss the efforts that the facility made towards achieving its goals and the reasons for failing to succeed. Depending on the likelihood of resolving cited deficiencies and stabilizing performance, CMS may use its discretion to terminate the facility’s participation in Medicare and Medicaid or continue working with the facility to improve its performance.

    To further incentivize facilities and ensure transparency, CMS will maintain a continuous listing of facilities participating in the SFF Program, the duration of their participation and their most recent survey results. Facilities that have graduated from the SFF Program may be downloaded from the CMS website for three years after their graduation; however, their designation as an SFF Program participating facility will be removed after graduation.

    Authors
    More insights

  • 2023 IP Outlook: What to Watch in Patent, Trademark and Copyright Law

    2023 IP Outlook: What to Watch in Patent, Trademark and Copyright Law

    ARTICLE / VIDEO

    2023 IP Outlook: What to Watch in Patent, Trademark and Copyright Law

    February 2, 2023

    Read time: 3 min

    Overview

    Coming out of 2022, developments around the globe are shaping the intellectual property (IP) landscape in the new year. We are seeing cases at the intersection of IP law and NFTs, the opening of the Unified Patent Court in Europe, and decisions from the Supreme Court of the United States and the Court of Appeals for the Federal Circuit affecting innovators and brand owners.

    McDermott’s 2023 IP Outlook examines the top trends and decisions in IP law from the past year and shares what you and your business should look out for in the year ahead. Watch the videos below and click on the title of each trend to read the corresponding report.

    Patent Trends

    Trademark and Copyright Trends

    In depth
    Conclusion
    More insights